FAQ - Our COVID-19 Vaccine

Concept of coronavirus COVID-19
Concept of coronavirus COVID-19

1. How are you contributing to the fight against COVID-19?

We have executed an extensive development program which was based on innovative and proven manufacturing technology to create our protein-based adjuvanted COVID-19 booster vaccine.  

Our COVID-19 vaccine was developed in partnership with GSK and BARDA and is approved in Europe. 

We are continuing to collect data and real-world evidence to help us understand how well our vaccine works over time.

2. Where is your vaccine made?

Our COVID-19 booster vaccine is produced in our European and US manufacturing sites.  

3. When will it be available to countries?

Our vaccine is approved in Europe.  Please check with your relevant health authorities for information on its availability in your country.  

4. What are the future plans for your vaccine? Do you plan to develop an Omicron adapted vaccine?

As COVID-19 continues to evolve, we are working with public health authorities around the world to respond appropriately. 

5. Can people receive your COVID-19 vaccine and the flu vaccine at the same time?

Many public health authorities and the World Health Organization (WHO) have advised that licensed COVID-19 vaccines (or boosters) and licensed flu vaccines can be given at the same time to help reduce the number of healthcare visits and provide timely protection against both diseases. 

6. Does Sanofi have an mRNA COVID-19 vaccine candidate?

On September 28, 2021, we reported positive phase 1/2 study interim results for our mRNA COVID-19 vaccine candidate. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply, we decided not to pursue the development of that candidate. 

The initial data confirmed the potential of Sanofi’s mRNA and Lipid nanoparticle (LNP) platform.  We are now focusing our mRNA resources in our newly created mRNA Center of Excellence to address other infectious diseases and therapeutics where there is a strong unmet need. 

MAT-GLB-2004043 v4 – 05/2023